Fahar Merchant

Fahar Merchant

Company: Medicenna Therapeutics

Job title: President & Chief Executive Officer


Co-Stimulation of Adaptive and Innate Immune Cells to Achieve Clinical Benefit with MDNA11, a Long-Acting ‘Beta-only’ IL-2 Super-Agonist 1:00 pm

MDNA11 is an albumin fusion to a variant of IL-2 bestowed with enhanced affinity for CD122 and deprived of CD25 binding, with the intent to selectively stimulate immune effector cells. The presentation will comprise: Preliminary results from the ongoing MDNA11 Phase 1/2 ABILITY Clinical Trial in patients with advanced solid tumors Emerging safety and clinical…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.